E-viri
Recenzirano
-
Nicolini, Franck E; Hayette, Sandrine; Legros, Laurence; Rousselot, Philippe; Maloisel, Frédéric; Tulliez, Michel; Guerci, Agnès; Charbonnier, Aude; Prébet, Thomas; Rigal-Huguet, Françoise; Chabane, Kaddour; Magaud, Jean-Pierre; Paillet, Carole; Pivot, Christine; Michallet, Mauricette
Leukemia research, 2011, Letnik: 35, Številka: 1Journal Article
Abstract This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-α 2a to Imatinib mesylate (IM) 600 mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients. The combination was generally well tolerated in the 15 evaluable patients. A significant reduction of the Ph1+ BM metaphases was observed in these poor prognosis patients, with 2 long-term CCyR including 2 MMR. After a median follow-up of 43 months, 93% of patients are alive. The addition of PegIFNα2a to IM600 is feasible, and able to overcome resistance within this context.
